Methods of treating breast cancer that overexpress AKT kinase
US10744148B2 · kind B2 · utility
0Cited by
0References
22Claims
0Family size
Inventors
Key dates
| Filing date | Apr 14, 2017 |
| Grant date | Aug 18, 2020 |
| Priority date | — |
| Expiry date | Jul 12, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/912
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.